ISRG HOLD at $440 target with $348 stop; trim 10-15% into $405-412 resistance, no new buying at $410, re-entry triggers tied to $450.90 breakout, ~$350 retest with macro stabilization, or dovish Fed shift; Q3 FY2026 earnings as binary catalyst.
HOLD ISRG at $440 price target with $348 stop-loss. Do NOT buy at $410 (upper Bollinger Band $411.92, failed 2-year range resistance, tight stop unattractive). Trim 10-15% into $405-412 resistance if overweight vs mandate. Aggressive add triggers: (a) confirmed close >$450.90 (200 SMA) on volume ≥1.5× 20-day average, OR (b) retest/hold of ~$350 with bullish divergence AND stabilizing macro (10Y below 4.5%), OR (c) dovish regime shift with Fed 2027 cuts priced. Q3 FY2026 earnings is the hard-dated forced re-decision catalyst regardless of outcome.
| Position | Action |
|---|---|
| Overweight vs mandate in $405-412 resistance zone | Trim 10-15% position |
| At $410 area (upper Bollinger Band $411.92, failed 2-year range resistance) | Do NOT initiate new buying |
| Price at ~$350 retest with bullish divergence AND macro stabilizing (10Y below 4.5%) | Aggressive add triggers activate |
| Confirmed close >$450.90 (200 SMA) on volume ≥1.5× 20-day average | Aggressive add triggers activate |
The market is handing a generational entry point—ISRG trades at a 2-year valuation low with accelerating fundamentals (15.4% YoY revenue growth in Q2 2026), 33.5x forward P/E at the bottom of its historical 35-55x range, and a fortress balance sheet, making this a compelling asymmetric setup for long-term compounder holders.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 392.74 | bullish |
| close_50_sma | 373.93 | bullish |
| close_200_sma | 450.90 | bearish |
| macd | 6.81 | bullish |
| macds (signal) | 2.90 | bullish |
| macdh (histogram) | +3.90 | bullish |
| rsi | 65.40 | neutral |
| boll (lower band) | 346.20 | neutral |
| boll (middle band) | 379.06 | neutral |
| boll (upper band) | 411.92 | neutral |
| atr | 11.37 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Retest/hold of ~$350 with bullish divergence AND stabilizing macro (10Y below 4.5%)
Then: Add position
ISRG's recurring revenue model is defensive against rate stress; capital spending deferrals actually drive trade-in upgrade cycles
↩ rebuts: “Bear Argument #1: Macro fear — hawkish Fed, 10-yr at 2007 highs”
· concedes: The 2027 per-procedure pricing cut is real and legitimate — management is deliberately taking price to expand the market to ASCs and new procedure types, trading 5-10% per-unit price for 30%+ volume opportunity in TAM expansion
ISRG's "generational entry point" is actually a valuation trap: the Q2'26 print was likely the last easy comp before the 2027 pricing reset compresses margins, macro headwinds (Fed hiking, 10-year at 2007 highs) will compress the 33.5x forward multiple by ~20%, and Medtronic Hugo's indication approvals signal the competitive threat is now rather than future. The stock has failed at this exact technical range twice in two years and remains 10.1% below the 200 SMA.
· concedes: Q2 revenue growth was real and strong at +15.4% YoY; Trade-ins did surge 74% YoY (144 vs. 83); Revenue model is ~70% recurring; TAM expansion via ASCs is a real structural opportunity; 33.5x forward P/E is at bottom of historical 35-55x range; Institutional bullish sentiment exists (even if from recycled content)
→ vs conservative: Waiting for macro clarity is itself a market-timing call; the 33.5x forward multiple IS the clarity, and waiting for 10-year to roll over before buying a 29% EPS compounder means buying 15-20% higher once pivot arrives
→ vs neutral: The fundamentals report's BUY rating at 33.5x forward P/E rests on $12.09 EPS that hasn't absorbed the 2027 pricing step-down; a 5-8% negative EPS revision flips the multiple from compelling to fair-to-expensive
| neutral |
| vwma | 379.58 | bullish |
Support: 346.2 · 379.06 · 383 · 392.74 | Resistance: 411.92 · 420 · 450.9
Short-term trend is firmly bullish with price $12.44 above the 10 EMA and holding above the 50 SMA for 9+ sessions; medium-term momentum is confirmed by MACD bullish crossover with expanding histogram and RSI at 65.40 leaving room for further upside before overbought territory; long-term trend remains bearish with price 10.1% below the 200 SMA. Near-term resistance sits at the upper Bollinger Band ($411.92), followed by $420 and the major pivot at $450.90 (200 SMA); support anchors at the 10 EMA ($392.74) with a risk-aware stop suggested at ~$383 (2× ATR). Volume character shows demand absorbing supply with VWMA lagging price by ~$25.60, but VWMA is still sloping soft indicating the broader tape is not yet fully healed.
Market Cap
$145.2B
P/E (TTM)
46.5x
Forward P/E
33.5x
PEG Ratio
1.86
P/B
7.89x
EV/EBITDA
~34.6x
Revenue (TTM)
$11.03B
Revenue YoY (Q2'26)
+15.4%
3-Yr Revenue CAGR
~17%
3-Yr EPS CAGR
~29%
Gross Margin
66.7%
Operating Margin
33.6%
Net Margin
28.4%
ROE
17.4%
ROA
10.5%
Diluted EPS (TTM)
$8.71
Forward EPS Estimate
$12.09
EBITDA (TTM)
$4.18B
Operating Cash Flow (TTM)
$3.71B
Free Cash Flow (TTM)
$2.62B
FCF Conversion
~83%
CapEx (TTM)
$484M
Cash & ST Investments
$5.22B
Long-Term Debt
$0
Current Ratio
4.96
Working Capital
$7.62B
Total Assets
$20.88B
Stockholders' Equity
$18.17B
Buybacks (LTM)
$3.56B
Share Count YoY Change
-1.3%
Shares Outstanding
~353.9M
52-Wk High
$603.88
52-Wk Low
$328.57
50-Day MA
$373.87
200-Day MA
$451.71
Beta
1.47
Drawdown from 52-Wk High
38%
2025 Revenue
$10.06B
2025 Net Income
$2.86B
2025 Diluted EPS
$7.87
2024 Revenue
$8.35B
2024 Net Income
$2.32B
2023 Revenue
$7.12B
2022 Revenue
$6.22B
Inventory (Q2 2026)
$2.03B
Receivables (Q2 2026)
$1.78B
Net PP&E
$5.55B
Total Liabilities
$2.58B
Q2 2026 Revenue
$2.89B
Q2 2026 Net Income
$818M
Q2 2026 EBITDA
$1.20B
Q2 2026 EBITDA Margin
41.6%
Strengths
Concerns
The analyst rates ISRG a BUY based on the combination of accelerating revenue growth (+15.4% YoY in Q2 2026), 30%+ EPS compounding trajectory toward ~$12.09 forward, and a compressed forward P/E of 33.5x that represents a 2-year relative low despite best-in-class 66.7% gross margins and a debt-free balance sheet with $5.22B cash. The 38% drawdown from the 52-week high is viewed as excessive given the fundamental trajectory, with aggressive $3.56B buyback activity signaling management confidence, though position sizing should reflect the elevated 1.47 beta.
Macro: Hawkish Fed regime: Fed hiked on Sep 16 (Dow down 600 pts), 96% probability of zero 2026 rate cuts (Polymarket), 10-yr Treasury at 2007 high (~5%), 30-yr at 2004 high; sticky CPI flagged by Jamie Dimon; mortgage rates creeping toward 7.5%; US recession probability 10% by EOY 2026 (+2 pp WoW); growth-inflation blend closer to reflation than recession. Friday relief: Trump–Xi dinner, easing yields, and weaker oil sparked a risk-on rally; S&P 500, Nasdaq, and Dow posted weekly gains. Iran tensions keep oil above $100/bbl; Polymarket assigns 2% odds of formal US-Iran war by year-end 2026. Macro regime = higher-for-longer rates + persistent inflation + geopolitical oil risk — historically a headwind for long-duration, premium-multiple growth names like ISRG.